Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.

@article{Misset1996AdjuvantTO,
  title={Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.},
  author={J. L. Misset and Mario di Palma and M del M Delgado and Robert Plagne and Ph Chollet and Pierre Fumoleau and Bernard Le M{\'e}vel and Dominique Belpomme and Jacques Guerrin and Pierre Fargeot and Ren{\'e} Metz and M Ithzaki and Catherine Hill and Georges Math{\'e}},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1996},
  volume={14 4},
  pages={1136-45}
}
PURPOSE To determine the long-term impact on disease-free survival (DFS) and overall survival (OS) of adjuvant anthracycline-based chemotherapy, when prospectively compared by random allocation with standard cyclophosphamide, methotrexate, and fluorouracil (CMF) in node-positive (N+) breast cancer patients. PATIENTS AND METHODS Two hundred forty-nine patients with N+ breast cancer, recruited from eight French cancer centers, were randomized to receive 12 monthly cycles of adjuvant… CONTINUE READING
23 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

Similar Papers

Loading similar papers…